ACVR1B and Familial prostate cancer: miR-185 could decrease prostatic cancer cell proliferation and HUVEC migration and angiogenesis, while overexpression of ALK4 in DU145 cells or LNCaP cells could suppress the effect of miR-185, indicating that miR-185 targeted ALK4 to regulate angiogenesis in prostate cancer.